Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-55920839 in Healthy Subjects and SLE
NCT02609789Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial of JNJ-55920839 in systemic lupus erythematosus (SLE) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Treatment Emergent Adverse Events at Week 22. Started Dec 2015; status: completed.
02
Drugs
JNJ-55920839
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02609789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609789.